U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860984) titled 'Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis' on March 01.
Brief Summary: Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition...